TheEdgeResearch
Home / Stocks / IMUC

EOM Pharmaceuticals Holdings, Inc. (IMUC)

OTC Healthcare Biotechnology
$0.24 ▲ +8.18%
Market Cap
$30.1M
Sector
Healthcare
Industry
Biotechnology
Beta
0.17
52-Wk Range
0.036-0.34
CEO
Irach Taraporewala
Country
US
Currency
USD

EOM Pharmaceuticals Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Montvale, NJ, US. The stock last traded at $0.24, up 8.18% on the session, giving a market capitalisation of $30.1M. On trailing twelve-month figures it carries a trailing P/E of -15.66, a net margin of 0.0%. Its beta of 0.17 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-15.66
Price / Sales
0.00
Price / Book
-12.58
EV / EBITDA
-17.42
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-0.73
Current ratio
0.08
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
3
IPO date
2021-01-08
Headquarters
Montvale, NJ, US
About EOM Pharmaceuticals Holdings, Inc.

EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medications. These treatments hold the potential to revolutionize existing therapeutic approaches. Among its key drug candidates currently undergoing development are EOM613 and EOM147. Established on March 20, 1987, the company maintains its corporate headquarters in Montvale, New Jersey.

Comparable companies

EOM Pharmaceuticals Holdings, Inc. is most often compared with the following Healthcare names:

DVHGFHMTXFHOOKLVCLFNYMXFOXBOFPPCBPRVCFQPTFFSRBCF
More research on IMUC
IMUC technical analysis IMUC TheEdge Score Compare against peers
Open full interactive analysis & DCF →